Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies.

Constantinescu, Catalin; Pasca, Sergiu; Zimta, Alina-Andreea; Tat, Tiberiu; Rus, Ioana; Teodorescu, Patric; Iluta, Sabina; Tanase, Alina; Colita, Anca; Sigurjonsson, Olafur; Einsele, Hermann; Tomuleasa, Ciprian.

Constantinescu C; Intensive Care Unit, Ion Chiricuta Clinical Cancer Center, 400010 Cluj Napoca, Romania.
Pasca S; Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400004 Cluj Napoca, Romania.
Zimta AA; Department of Anesthesia and Intensive Care, Iuliu Hatieganu University of Medicine and Pharmacy, 400000 Cluj Napoca, Romania.
Tat T; Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400004 Cluj Napoca, Romania.
Rus I; Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400000 Cluj Napoca, Romania.
Teodorescu P; Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400000 Cluj Napoca, Romania.
Iluta S; Intensive Care Unit, Ion Chiricuta Clinical Cancer Center, 400010 Cluj Napoca, Romania.
Tanase A; Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400014 Cluj Napoca, Romania.
Colita A; Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400004 Cluj Napoca, Romania.
Sigurjonsson O; Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400014 Cluj Napoca, Romania.
Einsele H; Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400004 Cluj Napoca, Romania.
Tomuleasa C; Department of Hematology, Ion Chiricuta Clinical Cancer Center, 400014 Cluj Napoca, Romania.